echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Samsung Bioepis's Beval sing-it-againbiolya AYBINTIO is positively rated by CHMP

    Samsung Bioepis's Beval sing-it-againbiolya AYBINTIO is positively rated by CHMP

    • Last Update: 2020-07-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    South Korea's Samsung Bioepis recently announced that the European DrugAdministrationBureau (EMA) of the Human Drug Commission (CHMP) is positive about AYBINTIO, the drug is a biosimilar of beflopaCHMP recommends the use of AYBINTIO for beta-suprothem-based indications, including metastaticcolorectal cancer(mCRC), metastaticbreast cancer(mBC), non-small cell lung cancer (
    NSCLC), metastatic renal cell cancer (mRCC), epithelialovarian cancer, primary peritonic cancer and cervical cancerThe European Commission (EC) will review CHMP's positive comments to decide whether to grant AYBINTIO marketing licences"High-quality biosimilars are an important means of reducing the financial burden on patients," said Hee Kyung Kim, senior vice president of clinical science at Samsung BioepisOnce approved, AYBINTIO will be an effective treatment option for different types of cancer and may help many patients in Europe."AYBINTIO's Market Authorization Application (MAA) is supported by pharmacokinetics (PK) and clinical data, as well as pharmacological and toxicological data, which show that AYBINTIO is highly similar to BevalsingIn addition, the company filed a biologics licensing application (BLA) for AYBINTIO in September 2019 and is currently under review by the U.S FDA
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.